Skip to main content

Table 1 Comparison of laboratory factors between MDS with low ApoA1 group and high ApoA1 group in 228 MDS patients

From: Decreased serum apolipoprotein A1 level predicts poor prognosis of patients with de novo myelodysplastic syndromes

Variable

All patients

Low ApoA1 group (n = 125)

High ApoA1 group (n = 103)

statistics

P value

Gender(n)

228

  

χ2 = 10.638

0.001

 Male/Female, n

133/95

85/40

48/55

  

Age [years, median (quartile)]

62(51,73)

63(28 ~ 86)

61(16 ~ 90)

Z = -1.881

0.06

BM Blast[%, median (quartile)]

4(1,9)

6(0 ~ 19.5)

3(0 ~ 19)

Z = -2.718

0.007

Peripheral Blood

 NE [× 109/L, median (quartile)]

1.2(0.7,2.1)

1.1(0 ~ 7.4)

1.3(1.1 ~ 6.9)

Z = -1.111

0.266

 HB [g/L, median (quartile)]

7.5(6.2,9.9)

67(22 ~ 142)

88(50 ~ 142)

Z = -5.315

<0.0001

 PLT [×109/L, median (quartile)]

52(28,94)

46(4 ~ 332)

60(2 ~ 434)

Z = -2.809

0.005

 ALB [g/L, median (quartile)]

39.4(35.4,43.0)

37.1(23.3 ~ 48.9)

42.0(18.3 ~ 60.2)

Z = -6.275

<0.0001

 CHO [mmol/L, median (quartile)

3.56(2.78,4.26)

3.13(1.28 ~ 7.62)

4.07(2.01 ~ 8.92)

Z = -6.564

<0.0001

 LDH [U/L, median (quartile)

205.5(167.0,269.8)

206(100 ~ 930)

203(94 ~ 618)

Z = -0.337

0.736

 CRP [mg/L, median (quartile)

2.24(0.83,6.13)

2.7(0.33 ~ 33.69)

1.53(0.15 ~ 19.21)

Z = -2.477

0.013

 HDL [mmol/L, median (quartile)

0.91(0.68,1.15)

0.73(0.09 ~ 1.48)

1.15(0.63 ~ 2.27)

Z = -10.316

<0.0001

 LDL [mmol/L, median (quartile)

2.08(1.60,2.59)

1.84(0.32 ~ 5.07)

2.33(0.8 ~ 5.75)

Z = -5.151

<0.0001

 ApoB [g/L, median (quartile)]

0.69(0.55,0.87)

0.63(0.23 ~ 1.29)

0.76(0.26 ~ 1.97)

Z = -4.670

<0.0001

 ApoA1[g/L, median (quartile)]

1.00(0.82,1.18)

0.84(0.34 ~ 1.02)

1.19(1.03 ~ 2.36)

Z = -12.989

<0.0001

2016 WHO classification

   

χ2 = 14.801

0.039

 MDS-SLD, % (n/n)

10.1% (23/228)

6.4% (8/125)

14.6% (15/103)

  

 MDS-MLD, % (n/n)

27.6% (63/228)

25.6% (32/125)

3.0% (31/103)

  

 MDS-RS-SLD, % (n/n)

2.2% (5/228)

1.6% (2/125)

2.9% (3/103)

  

 MDS-RS-MLD, % (n/n)

4.4% (10/228)

3.2% (4/125)

5.8% (6/103)

  

 MDS-5q-, % (n/n)

2.6% (6/228)

1.6% (2/125)

3.9% (4/103)

  

 MDS-EB1, % (n/n)

25.9% (59/228)

27.2% (34/125)

24.3% (25/103)

  

 MDS-EB2, % (n/n)

21.1% (48/228)

28.8% (36/125)

11.7% (12/103)

  

 MDS-U, % (n/n)

6.1% (14/228)

5.6% (7/125)

6.8% (7/103)

  

IPSS-R cytogenetic risk group

   

χ2 = 2.738

0.603

 Very good, % (n/n)

1.0% (2/194)

1.0% (1/97)

1.0% (1/97)

  

 Good, % (n/n)

63.9% (124/194)

59.8% (58/97)

68.0% (66/97)

  

 Intermediate, % (n/n)

20.6% (40/194)

24.7% (24/97)

16.5% (16/97)

  

 Poor, % (n/n)

5.2% (10/194)

4.1% (4/97)

6.2% (6/97)

  

 Very poor, % (n/n)

9.3% (18/194)

10.3% (10/97)

8.2% (8/97)

  

IPSS-R risk category

   

χ2 = 10.349

0.035

 Very low, % (n/n)

6.7% (13/194)

3.1% (3/97)

10.3% (10/97)

  

 Low, % (n/n)

18.6% (36/194)

14.4% (14/97)

22.7% (22/97)

  

 Intermediate, % (n/n)

34.5% (67/194)

34.0% (33/97)

35.1% (34/97)

  

 High, % (n/n)

21.1% (41/194)

22.7% (22/97)

19.6% (19/97)

  

 Very high, % (n/n)

19.1% (37/194)

25.8% (25/97)

12.4% (12/97)

  

IPSS-R score [median (quartile)]

4.5(3.0,6.0)

4.5(2.0 ~ 10.0)

4.0(1.0 ~ 9.0)

Z = -3.188

0.001

Gene mutation, % (n/n)

64.1% (41/64)

71.4% (20/28)

58.3% (21/36)

χ2 = 1.173

0.279

Leukemia transformation, % (n/n)

11.4% (26/228)

12.8% (16/125)

9.7% (10/103)

χ2 = 0.534

0.465

Complex karyotype, % (n/n)

18.0% (35/194)

21.6% (21/97)

14.4% (14/97)

χ2 = 1.708

0.191

With cardiovascular comorbidity, % (n/n)

21.9% (50/228)

21.6% (27/125)

22.3% (23/103)

χ2 = 0.018

0.895

  1. Abbreviations: BM bone marrow, NE neutrophil, HB hemoglobin, PLT platelet, ALB albumin, CRP C reactive protein, CHO cholesterol, LDH lactic dehydrogenase, HDL high-density lipoprotein, ApoB apolipoprotein B, LDL low-density lipoprotein, ApoA1 apolipoprotein A1, MDS-SLD MDS with single lineage dysplasia, MDS-MLD MDS with multilineage dysplasia, MDS-RS-SLD MDS with ring sideroblasts and single lineage dysplasia, MDS-RS-MLD MDS with ring sideroblasts and multilineage dysplasia, MDS-EB1 MDS with excess blasts 1, MDS-EB2 MDS with excess blasts 2, MDS-U unclassifiable, IPSS-R Revised International Prognostic Scoring System